Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia

BACKGROUND: Imatinib mesylate (IM) is a first-line treatment option for patients with chronic myeloid leukemia (CML). Patients who fail or are intolerant to IM therapy are treated with more expensive second and third-generation tyrosine kinase inhibitors. Patients show wide variation in trough conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kibum, McMillin, Gwendolyn A., Bernard, Philip S., Tantravahi, Srinivas, Walker, Brandon S., Schmidt, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927594/
https://www.ncbi.nlm.nih.gov/pubmed/31869360
http://dx.doi.org/10.1371/journal.pone.0226552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927594/
https://www.ncbi.nlm.nih.gov/pubmed/31869360
http://dx.doi.org/10.1371/journal.pone.0226552

Ejemplares similares